<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="177">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01951469</url>
  </required_header>
  <id_info>
    <org_study_id>NSCLC brain metastasis 01</org_study_id>
    <nct_id>NCT01951469</nct_id>
  </id_info>
  <brief_title>Gefitinib With or Without Pemetrexed/Cisplatin in Brain Metastases From Non-small Cell Lung Cancer</brief_title>
  <official_title>Multicenter Phase II Study of Gefitinib Mono-therapy or Gefitinib Combined With Pemetrexed/Cisplatin in Patients With Brain Metastases From Non-small Cell Lung Cancer Harboring EGFR Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wu Jieping Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center phase II randomized controlled study to assess the efficacy of
      Gefitinib alone and Gefitinib combinating with Pemetrexed/cisplatin on patients with brain
      metastasis from non-small cell lung cancer(NSCLC) harboring EGFR mutation type by
      intracranial PFS(iPFS),also PFS ,DCR and OS.The side effect is evaluated as well.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>comparing the difference of iPFS(intracranial progression free survival) in two arms</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>comparing the difference of Response rate(CR&amp;PR) and in two arms</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>PFS(Progression Free Survival)</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>OS(Overall Survival)</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Brain Metastases</condition>
  <condition>EGFR</condition>
  <arm_group>
    <arm_group_label>Gefitinib and Pemetrexed/cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gefitinib 250mg is Taken Orally on day 4-28,combined Pemetrexed/cisplatin chemotherapy on day 1-3, every 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gefitinib mono-therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gefitinib 250mg is Taken Orally everyday</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib and Pemetrexed/cisplatin</intervention_name>
    <description>Gefitinib 250mg is Taken Orally on day 4-28,combined Pemetrexed/cisplatin chemotherapy on day 1-3, every 28 days</description>
    <arm_group_label>Gefitinib and Pemetrexed/cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib mono-therapy</intervention_name>
    <description>Gefitinib 250mg is Taken Orally everyday</description>
    <arm_group_label>Gefitinib mono-therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient who was confirmed stage IV NSCLC with EGFR activating mutation and brain
             metastases by pathologic histology or cytology

          2. Patients who had never received therapy (including chemotherapy,WBRT,EGFR-TKI and
             EGFR monoclonal antibody) after diagnosed brain metastases

          3. Appraisable disease, the presence of at least three lesions if longest diameter &lt;10
             mm by brain MRI

          4. Adult patients (≥ 18 years). ECOG Performance Status 0 or 1 Life expectancy of at
             least 12 weeks.,Haemoglobin ³ 10.0 g/dl, Absolute neutrophil count (ANC) ³1.5 x
             109/L, platelets ³ 100 x 109/L. Total bilirubin £ 1.5 x upper limit of normal (ULN).
             ALT and AST &lt; 2.5 x ULN in the absence of liver metastases, or &lt; 5 x ULN in case of
             liver metastases. Creatinine clearance ³ 60ml/min (calculated according to
             Cockcroft-gault formula).

          5. Patients should be contraceptive during the period of the trial until 8 weeks after
             the last administration of icotinib.

          6. Able to comply with the required protocol and follow-up procedures, and able to
             receive oral medications.

        Exclusion Criteria:

          1. Patient was received irradiation of brain. Patient with meningeal metastases were
             confirmed by MRI or cytology test of cerebrospinal fluid.

          2. Patient is received the treatment of Phenytoin, carbamazepine, rifampicin,
             phenobarbital, or St. John's Wort.

          3. Patient was received EGFR Tyrosine Kinase Inhibitor or EGFR monoclonal antibody.

          4. Interstitial pneumonia.Pericardial effusion, pleural effusion is uncontrolled .

          5. Any unstable systemic disease (including active infection, uncontrolled hypertension,
             unstable angina, congestive heart failure, myocardial infarction within the previous
             year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic
             disease).

          6. Any significant ophthalmologic abnormality ,especially severe dry eye syndrome
             ,keratoconjunctivitis sicca,Sjogren syndrome,severe exposure keratitis or any other
             disorder likely to increase the risk of corneal epithelial lesions.

          7. Lack of physical integrity of the upper gastrointestinal tract, or malabsorption
             syndrome, or inability to take oral medication, or have active peptic ulcer disease.

          8. The symptoms of increased intracranial pressure are uncontrolled after dehydration
             and cortisone treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>li-kun Chen, MD</last_name>
    <phone>13798019964</phone>
    <email>chenlk@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University of Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>li-kun Chen, doctor</last_name>
      <phone>13798019964</phone>
      <email>chenlk@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>li-kun Chen, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 23, 2013</lastchanged_date>
  <firstreceived_date>September 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Li-kun Chen</investigator_full_name>
    <investigator_title>medical doctor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
